ReP USP - Resultado da busca

Artigo de periodico
An open-label randomized controlled parallel-group pilot study comparing the immunogenicity of a standard-, double-, and booster-dose regimens of the 2014 seasonal trivalent inactivated influenza vaccine in kidney transplant recipients (2022)
Odongo, Fatuma Catherine Atieno ; Braga, Patricia Emilia; Palacios, Ricardo; Miraglia, João Luiz ; Sartori, Ana Marli Christovam ; Ibrahim, Karim Yaqub; Lopes, Marta Heloisa ; Caiaffa-Filho, Helio Hehl; Timenetsky, Maria do Carmo Sampaio Tavares; Agena, Fabiana
Fonte: Transplantation. Unidade: FM
Assuntos: TRANSPLANTE DE FÍGADO, ESTUDOS RANDOMIZADOS, VACINAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ODONGO, Fatuma Catherine Atieno et al. An open-label randomized controlled parallel-group pilot study comparing the immunogenicity of a standard-, double-, and booster-dose regimens of the 2014 seasonal trivalent inactivated influenza vaccine in kidney transplant recipients. Transplantation, v. 106, n. 1, p. 210-220, 2022Tradução . . Disponível em: https://doi.org/10.1097/TP.0000000000003702. Acesso em: 02 nov. 2025.
APA
Odongo, F. C. A., Braga, P. E., Palacios, R., Miraglia, J. L., Sartori, A. M. C., Ibrahim, K. Y., et al. (2022). An open-label randomized controlled parallel-group pilot study comparing the immunogenicity of a standard-, double-, and booster-dose regimens of the 2014 seasonal trivalent inactivated influenza vaccine in kidney transplant recipients. Transplantation, 106( 1), 210-220. doi:10.1097/TP.0000000000003702
NLM
Odongo FCA, Braga PE, Palacios R, Miraglia JL, Sartori AMC, Ibrahim KY, Lopes MH, Caiaffa-Filho HH, Timenetsky M do CST, Agena F. An open-label randomized controlled parallel-group pilot study comparing the immunogenicity of a standard-, double-, and booster-dose regimens of the 2014 seasonal trivalent inactivated influenza vaccine in kidney transplant recipients [Internet]. Transplantation. 2022 ; 106( 1): 210-220.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1097/TP.0000000000003702
Vancouver
Odongo FCA, Braga PE, Palacios R, Miraglia JL, Sartori AMC, Ibrahim KY, Lopes MH, Caiaffa-Filho HH, Timenetsky M do CST, Agena F. An open-label randomized controlled parallel-group pilot study comparing the immunogenicity of a standard-, double-, and booster-dose regimens of the 2014 seasonal trivalent inactivated influenza vaccine in kidney transplant recipients [Internet]. Transplantation. 2022 ; 106( 1): 210-220.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1097/TP.0000000000003702
Artigo de periodico-carta/editorial
After the pandemic. [Editorial]: the role of science in the future of the countries (2020)
Palacios, Ricardo; Covas, Dimas Tadeu ; Júnior, Luiz Carlos Pereira; Cimerman, Sergio
Fonte: The Brazilian Journal of Infectious Diseases. Unidade: FMRP
Assuntos: PANDEMIAS, PESQUISA CIENTÍFICA, CIÊNCIA, INVESTIMENTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PALACIOS, Ricardo et al. After the pandemic. [Editorial]: the role of science in the future of the countries. The Brazilian Journal of Infectious Diseases. Salvador: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.bjid.2020.06.006. Acesso em: 02 nov. 2025. , 2020
APA
Palacios, R., Covas, D. T., Júnior, L. C. P., & Cimerman, S. (2020). After the pandemic. [Editorial]: the role of science in the future of the countries. The Brazilian Journal of Infectious Diseases. Salvador: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.bjid.2020.06.006
NLM
Palacios R, Covas DT, Júnior LCP, Cimerman S. After the pandemic. [Editorial]: the role of science in the future of the countries [Internet]. The Brazilian Journal of Infectious Diseases. 2020 ; 24( 3): 189-190.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.bjid.2020.06.006
Vancouver
Palacios R, Covas DT, Júnior LCP, Cimerman S. After the pandemic. [Editorial]: the role of science in the future of the countries [Internet]. The Brazilian Journal of Infectious Diseases. 2020 ; 24( 3): 189-190.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.bjid.2020.06.006
Artigo de periodico
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial (2020)
Kallás, Esper Georges ; Precioso, Alexander Roberto; Palacios, Ricardo; Thome, Beatriz; Braga, Patricia Emilia; Vanni, Tazio; Campos, Lucia M. A; Ferrari, Lilian; Mondini, Gabriella; Kalil Filho, Jorge Elias
Fonte: Lancet infectious diseases. Unidade: FM
Assuntos: ANTICORPOS, IMUNOGENICIDADE DA VACINA, MÉTODO DUPLO-CEGO, VÍRUS DA DENGUE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KALLÁS, Esper Georges et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet infectious diseases, v. 20, n. 7, p. 839-850, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1473-3099(20)30023-2. Acesso em: 02 nov. 2025.
APA
Kallás, E. G., Precioso, A. R., Palacios, R., Thome, B., Braga, P. E., Vanni, T., et al. (2020). Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet infectious diseases, 20( 7), 839-850. doi:10.1016/S1473-3099(20)30023-2
NLM
Kallás EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Kalil Filho JE. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial [Internet]. Lancet infectious diseases. 2020 ; 20( 7): 839-850.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S1473-3099(20)30023-2
Vancouver
Kallás EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Kalil Filho JE. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial [Internet]. Lancet infectious diseases. 2020 ; 20( 7): 839-850.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S1473-3099(20)30023-2
Artigo de periodico-carta/editorial
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial (2020)
Palacios, Ricardo; Patino, Elizabeth Gonzalez; Piorelli, Roberta de Oliveira; Conde, Monica Tilli Reis Pessoa; Batista, Ana Paula; Zeng, Gang; Xin, Qianqian; Kallas, Esper Georges ; Flores, Jorge; Ockenhouse, Christian F
Fonte: Trials. Unidade: FM
Assuntos: COVID-19, PANDEMIAS, VACINAS, VACINAÇÃO, ENVELHECIMENTO, INCIDÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PALACIOS, Ricardo et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial. Trials. London: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1186/s13063-020-04775-4. Acesso em: 02 nov. 2025. , 2020
APA
Palacios, R., Patino, E. G., Piorelli, R. de O., Conde, M. T. R. P., Batista, A. P., Zeng, G., et al. (2020). Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial. Trials. London: Faculdade de Medicina, Universidade de São Paulo. doi:10.1186/s13063-020-04775-4
NLM
Palacios R, Patino EG, Piorelli R de O, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial [Internet]. Trials. 2020 ; 21( 1):[citado 2025 nov. 02 ] Available from: https://doi.org/10.1186/s13063-020-04775-4
Vancouver
Palacios R, Patino EG, Piorelli R de O, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial [Internet]. Trials. 2020 ; 21( 1):[citado 2025 nov. 02 ] Available from: https://doi.org/10.1186/s13063-020-04775-4
Artigo de periodico
Development of vaccines against Zika virus (2018)
Poland, Gregory A.; Kennedy, Richard B.; Ovsyannikova, Inna G.; Palacios, Ricardo; Ho, Paulo Lee; Kalil Filho, Jorge Elias
Fonte: Lancet infectious diseases. Unidade: FM
Assuntos: DENGUE, ZIKA VÍRUS, FEBRE AMARELA SILVESTRE, TRANSMISSÃO DE DOENÇAS, VACINAS VIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POLAND, Gregory A. et al. Development of vaccines against Zika virus. Lancet infectious diseases, v. 18, n. 7, p. E211-E219, 2018Tradução . . Disponível em: https://doi.org/10.1016/S1473-3099(18)30063-X. Acesso em: 02 nov. 2025.
APA
Poland, G. A., Kennedy, R. B., Ovsyannikova, I. G., Palacios, R., Ho, P. L., & Kalil Filho, J. E. (2018). Development of vaccines against Zika virus. Lancet infectious diseases, 18( 7), E211-E219. doi:10.1016/S1473-3099(18)30063-X
NLM
Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL, Kalil Filho JE. Development of vaccines against Zika virus [Internet]. Lancet infectious diseases. 2018 ; 18( 7): E211-E219.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S1473-3099(18)30063-X
Vancouver
Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL, Kalil Filho JE. Development of vaccines against Zika virus [Internet]. Lancet infectious diseases. 2018 ; 18( 7): E211-E219.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S1473-3099(18)30063-X
Artigo de periodico
Epitope sequences in dengue virus NS1 protein identified by monoclonal antibodies (2017)
Rocha, Leticia Barboza; Alves, Rubens Prince dos Santos; Caetano, Bruna Alves; Pereira, Lennon Ramos; Mitsunari, Thais; Amorim, Jaime Henrique; Polatto, Juliana Moutinho; Botosso, Viviane Fongaro; Gallina, Neuza Maria Frazatti; Palacios, Ricardo; Precioso, Alexander Roberto; Granato, Celso Francisco Hernandes; Oliveira, Danielle Bruna Leal ; Silveira, Vanessa Barbosa da; Luz, Daniela; Ferreira, Luís Carlos de Souza ; Piazza, Roxane Maria Fontes
Fonte: Antibodies. Unidade: ICB
Assuntos: MICROBIOLOGIA, EPITOPOS, SEQUENCIAMENTO GENÉTICO, ZIKA VÍRUS, VÍRUS DA DENGUE, PROTEÍNAS RECOMBINANTES, ANTICORPOS MONOCLONAIS, GLICOPROTEÍNAS, REPLICAÇÃO VIRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROCHA, Leticia Barboza et al. Epitope sequences in dengue virus NS1 protein identified by monoclonal antibodies. Antibodies, v. 6, n. 4, p. 1-13, 2017Tradução . . Disponível em: https://doi.org/10.3390/antib6040014. Acesso em: 02 nov. 2025.
APA
Rocha, L. B., Alves, R. P. dos S., Caetano, B. A., Pereira, L. R., Mitsunari, T., Amorim, J. H., et al. (2017). Epitope sequences in dengue virus NS1 protein identified by monoclonal antibodies. Antibodies, 6( 4), 1-13. doi:10.3390/antib6040014
NLM
Rocha LB, Alves RP dos S, Caetano BA, Pereira LR, Mitsunari T, Amorim JH, Polatto JM, Botosso VF, Gallina NMF, Palacios R, Precioso AR, Granato CFH, Oliveira DBL, Silveira VB da, Luz D, Ferreira LC de S, Piazza RMF. Epitope sequences in dengue virus NS1 protein identified by monoclonal antibodies [Internet]. Antibodies. 2017 ; 6( 4): 1-13.[citado 2025 nov. 02 ] Available from: https://doi.org/10.3390/antib6040014
Vancouver
Rocha LB, Alves RP dos S, Caetano BA, Pereira LR, Mitsunari T, Amorim JH, Polatto JM, Botosso VF, Gallina NMF, Palacios R, Precioso AR, Granato CFH, Oliveira DBL, Silveira VB da, Luz D, Ferreira LC de S, Piazza RMF. Epitope sequences in dengue virus NS1 protein identified by monoclonal antibodies [Internet]. Antibodies. 2017 ; 6( 4): 1-13.[citado 2025 nov. 02 ] Available from: https://doi.org/10.3390/antib6040014
Artigo de periodico-carta/editorial
Another emerging arbovirus, another emerging vaccine: Targeting Zika virus [Editorial] (2016)
Palacios, Ricardo; Poland, Gregory A.; Kalil, Jorge
Fonte: Vaccine. Unidade: FM
Assuntos: ZIKA VÍRUS, VETORES, VÍRUS DA DENGUE, TRANSMISSÃO DE DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PALACIOS, Ricardo e POLAND, Gregory A. e KALIL, Jorge. Another emerging arbovirus, another emerging vaccine: Targeting Zika virus [Editorial]. Vaccine. Kidlington: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.vaccine.2016.03.059. Acesso em: 02 nov. 2025. , 2016
APA
Palacios, R., Poland, G. A., & Kalil, J. (2016). Another emerging arbovirus, another emerging vaccine: Targeting Zika virus [Editorial]. Vaccine. Kidlington: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.vaccine.2016.03.059
NLM
Palacios R, Poland GA, Kalil J. Another emerging arbovirus, another emerging vaccine: Targeting Zika virus [Editorial] [Internet]. Vaccine. 2016 ; 34( 20): 2291-2293.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.vaccine.2016.03.059
Vancouver
Palacios R, Poland GA, Kalil J. Another emerging arbovirus, another emerging vaccine: Targeting Zika virus [Editorial] [Internet]. Vaccine. 2016 ; 34( 20): 2291-2293.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.vaccine.2016.03.059

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Título da fonte

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada